Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01955226 · ClinicalTrials.gov registry record · NA
CHG Dressings in Children With Central Lines
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT01955226: Clinical Trial NA study, sponsored by Yale University.
NCT01955226 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01955226, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Tegaderm CHG clear dressing reduces the number of unscheduled central catheter dressing changes compared to standard clear Tegaderm IV dressing in pediatric patients between the ages of 2 months to 18 years with central venous access. Secondarily, we will monitor contact skin irritation and central line associated blood stream infections.
Primary Outcome
The policy at our institution is to change central catheter dressings every 7 days unless they are soiled or detached. We will document dressing changes for the duration of line use and document the reason for the dressing change.
Interventions
- OTHER Tegaderm CHG clear dressing
- OTHER Standard clear Tegaderm dressing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-05 |
| Phase | NA |
Why NCT01955226 stopped before completion
NCT01955226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Tegaderm CHG clear dressing is the first listed.
NCT01955226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01955226 about?
NCT01955226 is a clinical study titled "CHG Dressings in Children With Central Lines". The purpose of this study is to determine whether Tegaderm CHG clear dressing reduces the number of unscheduled central catheter dressing changes compared to standard clear Tegaderm IV dressing in pediatric patients between the ages of 2 months to 18 years with central venous access. Secondarily, we...
What is the current status of trial NCT01955226?
This trial is currently terminated. It is a NA study. The enrollment target is 16 participants. The study started on 2014-02. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01955226?
The interventions under investigation include: Tegaderm CHG clear dressing (OTHER), Standard clear Tegaderm dressing (OTHER).
Who is sponsoring clinical trial NCT01955226?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01955226's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia